SymBio Pharmaceuticals Limited (TYO:4582)
68.00
-2.00 (-2.86%)
Jun 19, 2026, 3:30 PM JST
SymBio Pharmaceuticals Revenue
SymBio Pharmaceuticals had revenue of 233.46M JPY in the quarter ending March 31, 2026, a decrease of -11.57%. This brings the company's revenue in the last twelve months to 1.28B, down -39.73% year-over-year. In the year 2025, SymBio Pharmaceuticals had annual revenue of 1.31B, down -46.70%.
Revenue (ttm)
1.28B
Revenue Growth
-39.73%
P/S Ratio
3.84
Revenue / Employee
14.03M
Employees
91
Market Cap
4.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.31B | -1.15B | -46.70% |
| Dec 31, 2024 | 2.45B | -3.14B | -56.13% |
| Dec 31, 2023 | 5.59B | -4.42B | -44.15% |
| Dec 31, 2022 | 10.01B | 1.75B | 21.21% |
| Dec 31, 2021 | 8.26B | 5.27B | 176.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharma Foods International | 67.00B |
| Fuso Pharmaceutical Industries,Ltd. | 62.17B |
| Nippon Chemiphar | 33.09B |
| Morishita Jintan | 12.69B |
| Wakamoto Pharmaceutical | 9.43B |
| Taiko Pharmaceutical | 6.16B |
| WDB coco | 4.82B |
| Solasia Pharma K.K. | 410.00M |